The finding is one of several significant new results featured in the briefing materials, which span 53 pages of data analyses from the agency and from Pfizer. On Thursday, FDA’s vaccine advisory panel will discuss these materials in advance of a vote on whether to recommend authorisation of Pfizer and BioNTech’s vaccine. Despite the early protection afforded by the first dose, it’s unclear how long that protection would last on its own, underscoring the importance of the second dose. But the results in the briefing materials indicate no such problem. The briefing materials also provide a deeper look at the safety of the vaccine.

Source: bd News24 December 08, 2020 13:41 UTC